Drugs that contain Fexofenadine Hydrochloride
1. Allegra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5738872 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5738872 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
Market Authorisation Date: 25 July, 1996
Treatment: Use in treating allergic reactions; Treatment of allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years and for the relief of symptoms associated wi...
Dosage: CAPSULE;ORAL; SUSPENSION;ORAL
ALLEGRA family patents
2. Allegra Allergy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older
Dosage: TABLET;ORAL
ALLEGRA ALLERGY family patents
3. Allegra Hives patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older
Dosage: TABLET;ORAL
ALLEGRA HIVES family patents
4. Children's Allegra Allergy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5738872 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
| US6723348 | CHATTEM SANOFI | Orodispersible tablets containing fexofenadine |
Nov, 2021
(2 years ago) | |
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies adults and children 6 years of age and older; Relief of symptoms associated with respiratory allergies and for the relief of symptoms associate...
Dosage: SUSPENSION;ORAL; TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S ALLEGRA ALLERGY family patents
5. Children's Allegra Hives patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5738872 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
| US6723348 | CHATTEM SANOFI | Orodispersible tablets containing fexofenadine |
Nov, 2021
(2 years ago) | |
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Market Authorisation Date: 24 January, 2011
Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older
Dosage: SUSPENSION;ORAL; TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S ALLEGRA HIVES family patents